Incyte- INCB39110 – Another JAK-Fruit in INCY’s Basket
Positive results from the PhII trial of INCB39110 (PhII, selective oral JAK 1 inhibitor, unpartnered) in pts with chronic plaque psoriasis who had inadequate response to prior topical therapies demonstrated proof-of-concept (PoC) in Chronic Plaque Psoriasis. At European Academy of Dermatology and Venereology (EADV) 2013, INCY presented exploratory efficacy analyses which suggested that efficacy was approximately equal in pts with >10% body surface area involvement and in pts with less 10% body surface area involvement prior to treatment. Data is comparable to PFE’s JAK1/3 inhibitor, Tofacitinib (Launched for RA – Xeljanz) and in light of current competition in plaque psoriasis market. For more detail, please read our report on INCY, released on Oct. 3, 2013, titled, 'INCB39110 – Another JAK-Fruit in INCY’s Basket'
